Parham Sadeghipour

Mar 20, 2024 | nature.com | Azita H. Talasaz |Parham Sadeghipour |John Eikelboom |Deborah M. Siegal |Manuel Monreal |David Jimenez | +8 more

AbstractBalancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal disorders is challenging because of the potential for interference with the absorption of antithrombotic drugs and for an increased risk of bleeding. In this Review, we address considerations for enteral antithrombotic therapy in patients with cardiovascular disease and gastrointestinal comorbidities.

Mar 20, 2024 | nature.com | Azita H. Talasaz |Parham Sadeghipour |John Eikelboom |Deborah M. Siegal |Manuel Monreal |David Jimenez | +8 more

AbstractBalancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal disorders is challenging because of the potential for interference with the absorption of antithrombotic drugs and for an increased risk of bleeding. In this Review, we address considerations for enteral antithrombotic therapy in patients with cardiovascular disease and gastrointestinal comorbidities.

Mar 19, 2023 | thieme-connect.de | Azita H. Talasaz |Virginia Commonwealth |Parham Sadeghipour |Rajaie Cardiovascular

Thromb Haemost DOI: 10.1055/a-2059-4844Stroke, Systemic or Venous Thromboembolism Funding The study was funded by the Rajaie Cardiovascular Medical and Research Center. Atorvastatin and matching placebo were provided by Sobhan Darou, which is not among the study sponsors.